Related references
Note: Only part of the references are listed.Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
Willi Sauerbrei et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
Willi Sauerbrei et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
A validated HPLC-MS/MS method for estimating the concentration of the ganglioside, G(D2), in human plasma or serum
C. M. Busch et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2018)
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
Ami V. Desai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Share Paper
